The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Since 2005, GLP-1 receptor (GLP-1R) agonists (GLP-1RAs) have been developed as therapeutic agents for type 2 diabetes (T2D). GLP-1R is not only expressed in pancreatic islets but also other organs, especially the lung. However, controversy on extra-pancreatic GLP-1R expression still needs to be furt...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Juan, Feng, Jia Nuo, Ling, Wenhua, Jin, Tianru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643154/
https://www.ncbi.nlm.nih.gov/pubmed/36386481
http://dx.doi.org/10.1016/j.apsb.2022.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643154/
https://www.ncbi.nlm.nih.gov/pubmed/36386481
http://dx.doi.org/10.1016/j.apsb.2022.06.003

Ejemplares similares